A
Akari Therapeutics, Plc (AKTX)
NCM – Real vaqt narxi. Valyuta: USD
3.06
-2.09 (-40.58%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
3.06
-2.09 (-40.58%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Akari Therapeutics, Plc, onkologiya kompaniyasi, saraton hujayralarini zaharli moddalar bilan o'ldiradigan antikor-dorilar kon'yugatlarini (ADC) ishlab chiqadi. Uning asosiy yuklamasi PH1 bo'lib, u spliceosomalar faoliyatini buzadi va qo'shimcha saraton hujayralarini o'ldirishga olib keladigan immunitet javobini qo'zg'atadi. Kompaniyaning asosiy mahsulot nomzodi AKTX-101 bo'lib, bu trop2-ni nishonga oluvchi preklinik bosqichdagi ADC bo'lib, u PH1 ni trop2 antitelasi bilan birlashtirib, o'pka, ko'krak, peshob pufagi, bosh va bo'yin, oshqozon, oshqozon osti bezi, yo'g'on ichak, prostata va boshqa qattiq o'sma saraton turlarini davolash uchun ishlatiladi. Uning yuklamalari PH1 ni o'z ichiga oladi, bu saraton hujayralaridagi RNKning splicingini buzish uchun mo'ljallangan spliceosom modulatori bo'lgan yangi yuklamadir. Kompaniya, shuningdek, PH1 ni yuklama sifatida ishlatib, turli qattiq o'sma saratonlarini davolash uchun mo'ljallangan yangi bispesifik ADC AKTX-102 ni ishlab chiqmoqda. Akari Therapeutics, Plc kompaniyasining shtab-kvartirasi Tampa, Florida shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Satyajit Mitra Ph.D. | Executive Director & Head of Oncology |
| Mr. Abizer Gaslightwala | CEO, President & Director |
| Mr. Kameel D. Farag | Interim Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-08 | S-1 | forms-1.htm |
| 2026-04-10 | POS AM | formposam.htm |
| 2026-04-02 | DRS | filename1.htm |
| 2026-03-30 | 10-K | form10-k.htm |
| 2026-03-17 | 8-K | form8-k.htm |
| 2026-03-02 | 8-K | form8-k.htm |
| 2026-02-02 | DEF 14A | formdef14a.htm |
| 2026-01-27 | CORRESP | filename1.htm |
| 2026-01-23 | S-1 | forms-1.htm |
| 2026-01-22 | PRE 14A | formpre14a.htm |